Eli Lilly drug prolongs patients' lives in lung cancer trial

02/20/2014 | Reuters

A late-stage trial showed Eli Lilly and Co.'s experimental drug ramucirumab, in combination with docetaxel, significantly improved survival and progression-free survival in patients with non-small cell lung cancer compared with a combination of placebo and docetaxel. Eli Lilly plans to submit the drug for regulatory review for this indication later this year. Ramucirumab is also under development for treatment of liver cancer and colorectal cancer.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI